Ilies Marc A, Masereel Bernard, Rolin Stéphanie, Scozzafava Andrea, Câmpeanu Gheorghe, Cîmpeanu Valentin, Supuran Claudiu T
University of Agricultural Sciences and Veterinary Medicine, Faculty of Biotechnologies, Department of Chemistry, B-dul Marasti nr. 59, 71331 Bucharest, Romania.
Bioorg Med Chem. 2004 May 15;12(10):2717-26. doi: 10.1016/j.bmc.2004.03.008.
A series of aromatic/heterocyclic sulfonamides incorporating adamantyl moieties were prepared by reaction of aromatic/heterocyclic aminosulfonamides with the acyl chlorides derived from adamantyl-1-carboxylic acid and 1-adamantyl-acetic acid. Related derivatives were obtained from the above-mentioned aminosulfonamides with adamantyl isocyanate and adamantyl isothiocyanate, respectively. Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and methazolamide. The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value. Their lipophilicity was propitious with the crossing of the blood-brain barrier (log k' > IAM > 1.35). The anticonvulsant activity of some of the best CA inhibitors reported here has been evaluated in a MES test in mice. After intraperitoneal injection (30 mg kg(-1)), compounds A8 and A9 exhibited a high protection against electrically induced convulsions (> 90%). Their ED50 was 3.5 and 2.6 mg kg(-1), respectively.
通过使芳族/杂环氨基磺酰胺与源自金刚烷-1-羧酸和1-金刚烷基乙酸的酰氯反应,制备了一系列含有金刚烷基部分的芳族/杂环磺酰胺。相关衍生物分别由上述氨基磺酰胺与金刚烷异氰酸酯和金刚烷异硫氰酸酯制得。其中一些衍生物对参与重要生理过程的两种人碳酸酐酶同工酶CA I和CA II表现出良好的抑制效力,与临床使用的药物乙酰唑胺和甲醋唑胺处于相同的数量级。测定了最佳碳酸酐酶抑制剂的亲脂性,并将其表示为实验性log k'IAM和理论ClogP值。它们的亲脂性有利于通过血脑屏障(log k'> IAM> 1.35)。本文报道的一些最佳碳酸酐酶抑制剂的抗惊厥活性已在小鼠的最大电休克(MES)试验中进行了评估。腹腔注射(30 mg kg(-1))后,化合物A8和A9对电诱导惊厥表现出高度保护作用(> 90%)。它们的半数有效剂量(ED50)分别为3.5和2.6 mg kg(-1)。